Waters recognizes Head of TGen's Center for Proteomics for research excellence

NewsGuard 100/100 Score

Waters Corporation (NYSE:WAT) today recognized the Center for Proteomics at the Translational Genomics Research Institute (TGen) as a Waters Center of Innovation.

In particular, Waters recognized Dr. Konstantinos Petritis, Head of TGen's Center for Proteomics, and his team for their leadership in the research of proteomics and biomarker discovery and verification.

In a ceremony at TGen's headquarters in Phoenix, Ariz., TGen President and Research Director Dr. Jeffrey Trent told TGen employees and representatives from Waters Corporation that TGen is moving with a great sense of urgency toward helping cancer patients.

"Whether it's through our discovery-based research or our clinical programs, our focus is to provide patient benefit as quickly as we can. My hope and expectation is that in many unique ways the Waters Centers of Innovation Program will help us accelerate our research and further our goal of providing personalized medicine to each patient in the future," said Dr. Trent.

"It was Dr. Trent's vision for translational medicine that led us to the relationship we have with TGen today. By formalizing our relationship with them we want to help TGen achieve its objectives and make personalized medicine a reality, partly by taking technology to the next level. I look forward to doing good science together for years to come," said Mark Groudas, Waters Sr. Vice President, Americas Business Operations.

TGen is now among an elite group of fewer than 20 partners worldwide that are part of the Waters Centers of Innovation. While most of the member institutes of this circle are well established, TGen (created in 2002) is one of the youngest organizations to be named.

"One of our core strengths is in biomarker discovery and verification. With the infrastructure we've put into place, we are making steady progress in the development of diagnostic and prognostic biomarkers for lung, colon, breast and pancreatic cancer as well as other diseases. We're thankful to Waters for their support of our programs, not just in terms of instrumentation, but in terms of their training, technical support and services," said Dr. Petritis.

Source: The Translational Genomics Research Institute

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings